Streetbeat News

Products Services

PCRFY

Panasonic Corp (PCRFY) plans to produce solid-state batteries for drones by 2029, according to a report by Nikkei. The company aims to commercialize the technology, which is expected to offer higher energy density and safety than current lithium-ion batteries.

Portfolio Pulse from Charles Gross

September 12, 2023 | 11:14 am

DNA

Ginkgo Bioworks has signed a deal with Ceres Nanosciences to bring pathogen monitoring capabilities to labs worldwide. The partnership aims to enhance the detection and monitoring of pathogens, potentially improving global health security.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:12 am

BTAI

Bioxcel Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to the use of sublingual dexmedetomidine for the treatment of agitation. The company plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations for IGALMI. The patent is expected to expire no earlier than December 29, 2037.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:10 am

TSLA

A video showing a wheel cap of Tesla's Cybertruck detaching on the freeway has raised safety concerns. The incident occurred near Fremont, California. The Cybertruck's delivery event is scheduled for later this year, and Tesla may need to address this issue promptly. Earlier, a German newspaper reported design flaws in the Cybertruck, including issues with suspension, body sealing, noise levels, handling, and braking.

Portfolio Pulse from Anan Ashraf

September 12, 2023 | 11:06 am

HUMA

Humacyte has announced positive topline results from its V005 Phase 2/3 trial of Human Acellular Vessel (HAV) in vascular trauma repair. The results showed that HAV had higher rates of patency, lower rates of amputation and infection, compared to historic synthetic graft benchmarks. The company plans to file a Biologics License Application (BLA) for the treatment of vascular trauma with the FDA in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:05 am

LYRA

Lyra Therapeutics announced that its BEACON Phase 2 study of LYR-220 for chronic rhinosinusitis in patients with prior ethmoid sinus surgery has met its primary endpoint. This positive result could potentially lead to a new treatment option for patients suffering from this condition.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:03 am

BHC

Bausch+Lomb has announced the U.S. commercial launch of Miebo, a prescription eye drop for the treatment of dry eye disease. Miebo is the first and only eye drop approved for directly targeting tear evaporation.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:01 am

TSVT

2seventy bio, Inc. (NASDAQ:TSVT) and JW Therapeutics have announced plans to expand their strategic partnership. The expansion will build upon the companies' cell therapy development platform, with the intention to add two additional candidates from the 2seventy portfolio, one for solid tumor indications and another for autoimmune disease.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 10:56 am

ANIP

The FDA has approved Ani Pharmaceuticals' Abbreviated New Drug Application for Estradiol Tablets USP. These tablets are the generic version of the reference listed drug Estrace.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 10:53 am